Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The ProductSeeking Alpha · 5 days ago
Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What HappenedDefense World · Oct 2, 2026
Braveheart Bio to Participate in Stifel Cardiometabolic ForumGlobeNewsWire · Sep 16, 2026
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Sep 8, 2026
Braveheart Bio to Participate in Cantor Global Healthcare ConferenceGlobeNewsWire · Sep 1, 2026
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?The Motley Fool · Aug 10, 2026Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.